>
Switch to:

VistaGen Therapeutics E10

: $-9.27 (As of Dec. 2021)
View and export this data going back to 2011. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

VistaGen Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2021 was $-0.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-9.27 for the trailing ten years ended in Dec. 2021.

As of today (2022-05-29), VistaGen Therapeutics's current stock price is $1.06. VistaGen Therapeutics's E10 for the quarter that ended in Dec. 2021 was $-9.27. VistaGen Therapeutics's Shiller PE Ratio of today is .


VistaGen Therapeutics E10 Historical Data

The historical data trend for VistaGen Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -13.64 -12.27 -11.13 -10.31

VistaGen Therapeutics Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.38 -10.31 -10.05 -9.79 -9.27

Competitive Comparison

For the Biotechnology subindustry, VistaGen Therapeutics's E10, along with its competitors' market caps and E10 data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

VistaGen Therapeutics E10 Distribution

For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's E10 distribution charts can be found below:

* The bar in red indicates where VistaGen Therapeutics's E10 falls into.



VistaGen Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, VistaGen Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2021 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-0.05/117.6295*117.6295
=-0.050

Current CPI (Dec. 2021) = 117.6295.

VistaGen Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201203 -3.632 96.783 -4.414
201206 -2.200 96.819 -2.673
201209 -2.400 97.633 -2.892
201212 -17.000 96.871 -20.643
201303 -3.200 98.209 -3.833
201306 -0.400 98.518 -0.478
201309 -1.370 98.790 -1.631
201312 -0.440 98.326 -0.526
201403 -1.640 99.695 -1.935
201406 -3.700 100.560 -4.328
201409 -1.900 100.428 -2.225
201412 -1.080 99.070 -1.282
201503 -4.500 99.621 -5.313
201506 -19.230 100.684 -22.467
201509 -5.260 100.392 -6.163
201512 -1.950 99.792 -2.299
201603 -3.630 100.470 -4.250
201606 -0.510 101.688 -0.590
201609 -0.420 101.861 -0.485
201612 -0.340 101.863 -0.393
201703 -0.310 102.862 -0.355
201706 -0.280 103.349 -0.319
201709 -0.530 104.136 -0.599
201712 -0.250 104.011 -0.283
201803 -0.189 105.290 -0.211
201806 -0.200 106.317 -0.221
201809 -0.300 106.507 -0.331
201812 -0.240 105.998 -0.266
201903 -0.150 107.251 -0.165
201906 -0.150 108.070 -0.163
201909 -0.130 108.329 -0.141
201912 -0.150 108.420 -0.163
202003 -0.070 108.902 -0.076
202006 -0.070 108.767 -0.076
202009 -0.050 109.815 -0.054
202012 -0.070 109.897 -0.075
202103 -0.164 111.754 -0.173
202106 -0.040 114.631 -0.041
202109 -0.070 115.734 -0.071
202112 -0.050 117.630 -0.050

Add all the adjusted EPS together and divide 10 will get our e10.


VistaGen Therapeutics  (NAS:VTGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


VistaGen Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Saxe Jon S director FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane officer: VP, CFO AND SECRETARY 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph director, officer: PRES./CHIEF SCIENTIFIC OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A. officer: VP CORPORATE DEVELOPMENT C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin officer: VP CORPORATE DEVELOPMENT 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie director, 10 percent owner, officer: PRESIDENT 13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)